Studies in vivo and in vitro have shown that insulinstimulated adipocyte lipolysis rates are higher in obese White than Black South African women. The aims of this study were to determine whether adipocyte glucose uptake displays a similar trend and how weight loss affects adipocyte size and insulin sensitivity. METHODS: Abdominal and femoral adipocytes were isolated from 10 Black (OBW) and 10 White (OWW) obese women and insulin-stimulated glucose uptake measured using 14 C-glucose. In 5 OWW adipocyte glucose uptake was measured before and after weight loss induced by treatment with a nonsystemic agent (orlistat) over a 3 month period. RESULTS: Basal glucose uptake (i.e. in absence of insulin) was higher in abdominal adipocytes from OBW than those from OWW (2.9 AE 0.4 versus 1.6 AE 0.2 pmola10 6 cellsah; p`0.05) and insulin only stimulated glucose uptake signi®cantly in femoral adipocytes from OWW (1.3 AE 0.2 in absence of insulin versus 4.11 AE 1.17 pmola10 6 ah in the presence of 0.7 nmolal insulin). A mean weight loss of 10 AE 5% of body weight was accompanied by a decrease in adipocyte size (118.4 AE 5.3 to 110.4 AE 2.7 um; p`0.05) and a tendency for insulin stimulated-glucose uptake (expressed as % of basal uptake) to increase in abdominal adipocytes (47.5 AE 17.8 increased to 224.2 AE 67.2%; p 0.08).
INTRODUCTION:
Studies in vivo and in vitro have shown that insulinstimulated adipocyte lipolysis rates are higher in obese White than Black South African women. The aims of this study were to determine whether adipocyte glucose uptake displays a similar trend and how weight loss affects adipocyte size and insulin sensitivity. METHODS: Abdominal and femoral adipocytes were isolated from 10 Black (OBW) and 10 White (OWW) obese women and insulin-stimulated glucose uptake measured using 14 C-glucose. In 5 OWW adipocyte glucose uptake was measured before and after weight loss induced by treatment with a nonsystemic agent (orlistat) over a 3 month period. RESULTS: Basal glucose uptake (i.e. in absence of insulin) was higher in abdominal adipocytes from OBW than those from OWW (2.9 AE 0.4 versus 1.6 AE 0.2 pmola10 6 cellsah; p`0.05) and insulin only stimulated glucose uptake signi®cantly in femoral adipocytes from OWW (1.3 AE 0.2 in absence of insulin versus 4.11 AE 1.17 pmola10 6 ah in the presence of 0.7 nmolal insulin). A mean weight loss of 10 AE 5% of body weight was accompanied by a decrease in adipocyte size (118.4 AE 5.3 to 110.4 AE 2.7 um; p`0.05) and a tendency for insulin stimulated-glucose uptake (expressed as % of basal uptake) to increase in abdominal adipocytes (47.5 AE 17.8 increased to 224.2 AE 67.2%; p 0.08).
CONCLUSIONS: These data demonstrate that glucose uptake is less sensitive to insulin in adipocytes from OBW than OWW. Higher basal glucose uptake in the abdominal adipocytes from OBW than OWW suggests that non-insulin stimulated glucose uptake is greater in adipocytes from the former group. Furthermore, a small weight loss in OWW leads to a fall in adipocyte size and a small increase in adipocyte insulin sensitivity.
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Adipogenic effects of leptin are mediated by functional leptin receptors in rat preadipocytes Leptin, the product of ob gene, is mainly produced by white adipocytes and acts through speci®c receptors present in various cells. In this study, we have ®rst identi®ed the expression (mRNA and protein) of both short (Ob-Ra) and long (Ob-Rb) isoforms of leptin receptors, in rat preadipocytes during adipogenesis from various anatomical localizations (femoral subcutaneous and perirenal fat depots). In preadipocytes from the two localizations, expression levels of Ob-Ra and Ob-Rb increase during adipogenesis and are higher for both subtypes in perirenal than in subcutaneous depots. Moreover, Ob-Ra is more predominant than Ob-Rb in both localizations. Second, the functionality of the leptin receptor was investigated, during adipogenesis. The phosphorylation of both p42ap44 MAPkinase isoforms and STAT3 transcriptional factor were measured after a short exposure time to 10 nM leptin. Leptin increased phosphorylation of p42ap44 MAPkinase isoforms in con¯uent and differentiated preadipocytes from subcutaneous and perirenal fat depots. Moreover, the phosphorylation of STAT3 was also increased by leptin in con¯uent subcutaneous and differentiated perirenal preadipocytes. Finally, as leptin has been implicated in proliferation and differentiation processes in other cell types, we have studied, the in vitro effect of leptin on proliferation and differentiation of preadipocytes from subcutaneous fat depots. Leptin enhanced proliferation by 40% ( 3 [H] thymidine incorporation and cell counting) and differentiation by 50% (GPDH activity and LPL mRNA) with a parallel increase of PPARg2 mRNA levels.
Altogether, these results demonstrate for the ®rst time the presence of functional leptin receptors in rat preadipocytes. Moreover, these results indicate that, in subcutaneous preadipocytes, at least, leptin is able to control the adipoconversion process.
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Role of the circulating soluble leptin receptor in leptin resistance in humans 
INTRODUCTION:
One of the alternatively spliced transcripts of the leptin receptor lacks of intracellular-transmembrane domain and is a putative soluble leptin receptor (SLR). In the present study, we investigated if the differences of repartition of free and bound leptin between obese and lean patients might be related to their different levels of SLR in plasma. METHODS: Subjects of the study were divided in three group; obese (26 men and 92 women; BMI 30±44 kgam 2 ); overweight (11 men and 29 women; BMI 25±30 kgam 2 ) and lean (16 men and 48 women; BMI 18±25 kgam 2 ). A direct double monoclonal ELISA was developed to measure SLR using a monoclonal antibody and the recombinant human leptin receptor extracellular domain. Leptin measurement was done by RIA (Linco Research Inc). RESULTS: The recombinant SLR was able to bind human leptin with a Kd of 3 nM (by surface plasmon resonance). Our ELISA was speci®c to SLR and demonstrated no interference with leptin concentrations, indicating that it measured total plasma SLR. The intra-assay and inter-assay coef®cient of variations were 2.8% and 8.3%, respectively. In human plasma, SLR levels range from 10.6 to 100.9 ngaml. Leptin levels were more elevated in obese (34.0 AE 16.0 ngaml) than in overweight (20.5 AE 12.8 ngaml) and lean subjects (9.8 AE 8.2 ngaml). Surprisingly, SLR levels were more elevated in lean (51.2 AE 12.5 ngaml) than overweight (40.2 AE 14.9 ngaml) and obese (28.7 AE 8.8 ngaml) subjects (ANOVA; p`0.0001). SLR levels were more elevated in men (46.0 AE 15.2 ngaml) than in women (34.9 AE 13.9 ngaml) but this difference disappeared after adjustment by fat mass. Individual SLR levels were inversely correlated to body weight, BMI, fat mass (measured by DEXA), percent of fat mass and leptin levels (respectively r 2 0.33; r 2 0.49; r 2 0.58; r 2 0.57; r 2 0.56; p`0.0001). CONCLUSION: The soluble leptin receptor is present in human plasma where it binds leptin. Its level is inversely related to the degree of obesity, indicating a possible role in modulating the effect of leptin on body weight. The low level observed in obese patients could not be responsible for a decrease in free leptin in circulation. Inversely, a possible role of the soluble leptin receptor would be to maintain an active pool of bound leptin protected from metabolic clearance mechanisms. Therefore, low level of the soluble leptin receptor would contribute to the leptin resistance observed in obese patients by increasing the clearance of leptin. Alteration in the GH-IGF axis is observed in the obese state and IGF-I plays a role in the process of preadipocyte differentiation. In the light of the increased recognition of the endocrine role of the adipose tissue we have made a more detailed investigation of the local production of IGFs and IGFBPs in human adipose tissue. Subcutaneous human adipose tissue fragments (500 mg adipose tissue per incubation) or adipocytes in primary cultures were incubated for up to 48 h with various additions. The gene expression of IGF-I, IGF-II and IGFBPs were determined by real time RT-PCR and the media were analyzed for ultra®ltered free and total extractable IGF-I and -II by speci®c immunoassays whereas IGFBPs were determined by Western ligand blotting. RESULTS: Both IGF-I and -II were highly expressed in adipose tissue and IGF-II was both more pronouncedly expressed and produced than IGF-I by 4±5 fold (248 AE 68 ngaL versus 1123 AE 389 ngaL released to the medium for 48 h). IGFBP-4 was highly expressed and the protein was reproducably detected in the medium. IGFBP-5 was highly expressed by PCR but the BP-5 protein could not be detected by the antibodies used. IGFBP-2 was expressed to some extent and by Western ligand blot two low-molecular fragments were detected which are suggested to represent degradation products of BP-2 in the incubation medium. IGFBP-1 and 3 were not expressed in human adipose tissue. GH had a signi®cant stimulatory effect on IGF-I and IGFBP-5 (P`0.01) whereas dexamethasone signi®cantly inhibited IGF-II (P`0.05). The cytokines IL-1b, TNFa and IL-6 were also investigated. IL-6 had no effects whereas both IL-1b (2 ngaml) and TNFa (10 ngaml) had signi®cantly inhibitory effects on the productionaexpression of IGF-I, IGF-II, BP-2, BP-4, and BP-5. CONCLUSION: IGF-I, IGF-II, BP-2, BP-4 and (BP-5) are all expressed and produced in human adipose tisssue. These proteins are differentially regulated by GH and dexamethasone and strongly inhibited by the cytokines IL-1b and TNFa. These ®ndings indicate that the IGF system may play an important role in adipose tissue metabolism and, in addition, may be involved in some of the effects mediated by GH, cortisol and cytokines on the adipose tissue.
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Obesity related consequences on health in adult life an empirical approach 
INTRODUCTION:
Obesity has enormous impact on the incidence of chronic disease, such as cardiovascular disease and work disability. The present study estimates the number of extra years that obese subjects suffer from cardiovascular disease, use of medication due to chronic disease, and work disability, using empirical data and taking the relation between obesity and increased mortality into account.
METHODS:
We followed a representative cohort of the Finnish population, 19 518 men and women aged 20 to 92 years (mean: 44 years), for 15 years. Participation rate was 83%. We measured body mass index at baseline and de®ned categories of overweight according to the WHO guidelines. We measured hospitalisation for cardiovascular diseases and use of medication due to chronic diseases, work disability and all-cause mortality during followup by record linkage using the Finnish personal identity code. RESULTS: Relative risks of obesity for morbidity and disability exceeded those for mortality, and were highest in the youngest age groups. During a maximal follow-up of 15 years, obese men (BMI ! 30 kgam 2 ) had 0.29, and 1.96, and 0.50 extra years of cardiovascular diseases, reimbursed chronic medication, and work disability, respectively. Obese women suffered respectively 0.51, 1.95 and 0.94 extra years from these conditions. CONCLUSION: Obesity has a lifetime impact on health in adult life. The present study provides empirical evidence that obesity, unlike for instance smoking, is related to an increased time suffering from chronic morbidity and disability. The neuropeptide Y (NPY) system has a multitude of effects and is particularly well known for its role in appetite regulation. From studies conducted using selective agonists and antagonists, antisense approaches and knockout techniques, the Y1 and Y5 receptors have been suggested to mediate the stimulatory effect of NPY on food intake in rats and mice. The role of receptors may differ between species, and therefore we have decided to examine the effects of NPY on feeding behaviour in guinea pigs, which is evolutionary equally distantly related to human and rat. Male Dunkin-Hartley guinea pigs weighing 300±500 g were used. The guinea pigs were anaestezised by i.p. injection of a 1:3 mixture of Rompun vet. (20 mgaml) and Ketalar (50 mgaml). They were ®xed to stereotaxic frame. The skull was exposed and a stainless steel cannula (22 gauge) was implanted above the III ventricle to the depth of 6 mm from the bregma. The guide cannula was ®xed with screws and dental cement, and closed with a stylet. After the surgical operation, the guinea pigs were housed singly and allowed to recover for 7 days before the experiments begun.
Different doses of NPY or related peptides PYY, (Leu 31 -Pro 34 )NPY, NPY(2±36) or NPY(13±36) were infused into the III ventricle at a rate of 5 ml per min. The infusion volume was 10 ml. The controls received saline. After drug administration, the animals were returned to their cages, where they had free access to powdered feed (K5) and tap water. Food and water consumptions were measured 1, 2, 3 and 4 h after the drug treatment. Eating parameters (eating and drinking frequencies, meal duration, etc.) and behavioural parameters were studied using video camera technique. At the end of the experiment, the correct cannula placements were veri®ed by dye infusion.
NPY dose-dependently increased food intake in guinea pigs. It enhanced also drinking. The effective dose range for guinea pig was comparable to that reported for rats. Behavioural analysis showed that NPY increased eating frequency, the amount of time spent on eating and moving with no alteration in average meal duration. In addition to NPY, PYY, (Leu 31 -Pro 34 )NPY and NPY(2±36) stimulated feeding, whereas the Y2 receptor agonist, NPY(13±36), was inactive.
Potent appetite stimulation after NPY, PYY, (Leu 31 -Pro 34 )NPY and NPY(2±36) suggest that the Y5 receptor, but possibly also the Y1 receptor, mediate the NPY-induced food intake in guinea pigs. However, further studies with selective receptor antagonists are needed to determine the contribution of the receptor subtype(s) to the orexiogenic action of NPY.
